NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health

by NASDAQ Market News June 4, 2019

NASDAQ Market News
Click here to email author

ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis

VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today

Ads